StreetInsider.com News Articles

Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)

Mon, 13 Jul 2026 07:46:27 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $1,200.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).

The analyst commented: "43 Frequently Asked Questions on Ulixacaltamide's History & New Tablemania; Over the last few months, there has been a wave of new investor interest in PRAX as we near the PDUFA dates for ulixacaltamide in ET (January 29th) and relutrigine in SCN2A/8A DEEs (December 27th). Thus, we compiled this comprehensive deepdive reviewing the history of ulixacaltamide, including its depth of clinical data across ~10 studies and n=~1,150+ ET patients. Further, we review the Essential3 interim analysis, explaining the

Goldman Sachs Starts Praxis Precision Medicines Inc. (PRAX) at Buy

Mon, 13 Jul 2026 05:07:13 -0400

Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Buy rating and a price target of $447.00.

The analyst comments "We initiate coverage of Praxis Precision Medicines (PRAX) with a Buy rating and a 12-month price target of $447 (70%-weighted DCF value of $419, 30%-weighted M&A value of $514; M&A rank of 1). PRAX is a clinical-stage biotech company with two potential drug approvals - ulixacaltamide in essential tremor (ET) and relutrigine in genetic (SCN2A/8A-DEE) epilepsy - by January 2027. Our Buy thesis is underpinned by our view of: i) a novel standard of

Goldman Sachs Starts Praxis Precision Medicines Inc. (PRAX) at Buy

Mon, 13 Jul 2026 05:07:13 -0400

Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicines Inc. (NASDAQ: PRAX) with a Buy rating and a price target of $447.00.

Form 4 Praxis Precision Medicin For: Jul 08 Filed by: Souza Marcio

Wed, 08 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748164.html

Form 4 Praxis Precision Medicin For: Jul 08 Filed by: Souza Marcio

Wed, 08 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260708/26748164.html

Form 8-K Praxis Precision Medicin For: Jul 07

Tue, 07 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26742593.html

Form 8-K Praxis Precision Medicin For: Jul 07

Tue, 07 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26742593.html

Praxis strikes deal with Remagine Labs on transdermal ET drug patch

Tue, 07 Jul 2026 08:00:34 -0400

Praxis Precision Medicines (NASDAQ: PRAX) and Remagine Labs have entered a research collaboration and license agreement to develop an iontophoretic transdermal patch for ulixacaltamide, Praxis's T-type calcium channel inhibitor in development for essential tremor (ET), according to a press release.

Under the agreement, the companies will apply Remagine's electronically controlled transdermal delivery platform to ulixacaltamide, which is currently being reviewed as an oral therapy by the FDA. The FDA accepted Praxis's New Drug Application for ulixacaltamide in April 2026 and set a PDUFA target action date of January 29, 2027. The drug received Breakthrough Therapy Designation in December 2025.

Praxis has also

Praxis strikes deal with Remagine Labs on transdermal ET drug patch

Tue, 07 Jul 2026 08:00:34 -0400

Praxis has also

Praxis strikes deal with Remagine Labs on transdermal ET drug patch

Tue, 07 Jul 2026 08:00:34 -0400

Praxis has also

Praxis strikes deal with Remagine Labs on transdermal ET drug patch

Tue, 07 Jul 2026 08:00:34 -0400

Praxis has also

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Tue, 07 Jul 2026 08:00:00 -0400

Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route

Potential to expand the addressable market for ulixacaltamide beyond the initial patient population and to enable additional life-cycle management opportunities